Skip to main content
NCBI home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2008 Apr;69(2):104–117. doi: 10.1016/j.curtheres.2008.04.008

Effectiveness and tolerability of warm-supplementing kidney yang added to risperidone in improving cognitive impairment in patients with schizophrenia: An 8-week, multicenter, randomized, double-blind, placebo-controlled clinical trial

Zhen-hua Chen 1, Gao-hua Wang 1,a, Xiao-ping Wang 1, Ren-yun Chen 2, Hui-lin Wang 1, Ming-hua Yang 3, Yun-xiang Huo 2, Hong-bing Mei 2
PMCID: PMC3969969  PMID: 24692790

Abstract

Background: Certain herbal medicines have been reported to be effective in the treatment of psychiatric conditions, and combination treatment with drugs and herbal medicines has been reported to be useful in enhancing treatment efficacy and reducing recovery time and adverse events (AEs).

Objective: The purpose of this study was to investigate the effectiveness and tolerability of warm-supplementing kidney yang (WSKY) added to risperidone in improving cognitive impairment and negative symptoms (ie, cognitive function) in patients with schizophrenia.

Methods: This 8-week, multicenter, randomized, double-blind, placebo-controlled clinical trial was conducted in patients who met the clinical classification for schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Patients were recruited from 3 centers (including inpatient and outpatient clinics) and were evenly randomized to receive WSKY or placebo added to risperidone for 8 weeks. Primary assessments were conducted at weeks 2, 4, and 8. A clinical response was defined as a ≥50% reduction score (from baseline) on the Positive and Negative Syndrome Scale (PANSS), a ≥30% reduction score (from baseline) on the Scale for the Assessment of Negative Symptoms (SANS), or a ≥50% reduction score (from baseline) on the Hamilton Rating Scale for Depression (HAM-D-17). Cognitive function was assessed using the Wisconsin Card Sorting Test (WCST) at baseline and end point. Extrapyramidal AEs were assessed weekly using the Abnormal Involuntary Movement Scale (AIMS) and the Rating Scale for Extrapyramidal Side Effects (RSESE). AEs were assessed by patient interviews conducted at each clinic visit and also by the Treatment Emergent Symptoms Scale (TESS) scores.

Results: One-hundred twenty patients (62 males, 58 females; mean [SD] age, 34.4 [9.4] years; range, 18–45 years; baseline mean [SD] PANSS score, 88.7 [12.3]) were included in this study. Risperidone- and WSKY-treated patients had statistically significant improvements at end point in the number of completed categories (P = 0.019), perseverative responses (P = 0.041), perseverative errors (P = 0.040), and total errors (P = 0.049) on the WCST compared with placebo. The improvements in the PANSS, SANS, and HAM-D-17 scores were not significantly different between the 2 groups at week 8 for observed case and last-observation-carried-forward (LOCF) analyses. The response rates (LOCF) for the PANSS scores in the WSKY and placebo groups were 55.0% and 35.0%, respectively (P = 0.028), while the SANS scores were 63.3% and 45.0% (P = 0.044) and the HAM-D-17 were 35.0% and 45.0% (P = 0.264). There were no significant between-group differences in scores on the AIMS, RSESE, or TESS.

Conclusions: The results of this study suggest that WSKY added to risperidone significantly improved cognitive function in these patients, as measured by the number of completed categories, perseverative responses, perseverative errors, and total errors on the WCST compared with placebo. The response rates in the WSKY group for the PANSS and SANS scores were significantly higher compared with placebo. All treatments were generally well tolerated.

Key words: traditional Chinese medicine, schizophrenia, cognitive function, warm-supplementing kidney yang, WSKY, negative symptoms

Full Text

The Full Text of this article is available as a PDF (1.3 MB).

Contributor Information

Zhen-hua Chen, Email: chenzh@163.com.

Gao-hua Wang, Email: wanggaohuad@163.net.

References

  • 1.Heaton RK, Gladsjo JA, Palmer BW. Stability and course of neuropsychological deficits in schizophrenia. Arch Gen Psychiatry. 2001;58:24–32. doi: 10.1001/archpsyc.58.1.24. [DOI] [PubMed] [Google Scholar]
  • 2.Kirkpatrick B, Fenton WS, Carpenter WT, Jr, Marder SR. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006;32:214–219. doi: 10.1093/schbul/sbj053. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Murphy BP, Chung YC, Park TW, McGorry PD. Pharmacological treatment of primary negative symptoms in schizophrenia: A systematic review. Schizophr Res. 2006;88:5–25. doi: 10.1016/j.schres.2006.07.002. [DOI] [PubMed] [Google Scholar]
  • 4.Schuepbach D, Hill SK, Sanders RD. Early treatment-induced improvement of negative symptoms predicts cognitive functioning in treatment-naive first episode schizophrenia: A 2-year follow up. Schizophr Bull. 2004;30:837–848. doi: 10.1093/oxfordjournals.schbul.a007136. [DOI] [PubMed] [Google Scholar]
  • 5.Voruganti LN, Heslegrave RJ, Awad AG. Neurocognitive correlates of positive and negative syndromes in schizophrenia. Can J Psychiatry. 1997;42:1066–1071. doi: 10.1177/070674379704201008. [DOI] [PubMed] [Google Scholar]
  • 6.Hawkins KA, Hoffman RE, Quinlan DM. Cognition, negative symptoms, and diagnosis: A comparison of schizophrenic, bipolar, and control samples. J Neuropsychiatry Clin Neurosci. 1997;9:81–89. doi: 10.1176/jnp.9.1.81. [DOI] [PubMed] [Google Scholar]
  • 7.Riedel M, Spellmann I, Strassnig M. Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms. Eur Arch Psychiatry Clin Neurosci. 2007;257:360–370. doi: 10.1007/s00406-007-0739-x. [DOI] [PubMed] [Google Scholar]
  • 8.Tamminga CA, Buchanan RW, Gold JM. The role of negative symptoms and cognitive dysfunction in schizophrenia outcome. Int Clin Psychopharmacol. 1998;13:S21–S26. doi: 10.1097/00004850-199803003-00004. [DOI] [PubMed] [Google Scholar]
  • 9.Heydebrand G, Weiser M, Rabinowitz J. Correlates of cognitive deficits in first episode schizophrenia. Schizophr Res. 2004;68:1–9. doi: 10.1016/S0920-9964(03)00097-5. [DOI] [PubMed] [Google Scholar]
  • 10.Beasley CM, Jr, Tollefson G, Tran P. Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 1996;14:111–123. doi: 10.1016/0893-133X(95)00069-P. [DOI] [PubMed] [Google Scholar]
  • 11.Lieberman JA, Safferman AZ, Pollack S. Clinical effects of clozapine in chronic schizophrenia: Response to treatment and predictors of outcome. Am J Psychiatry. 1994;151:1744–1752. doi: 10.1176/ajp.151.12.1744. [DOI] [PubMed] [Google Scholar]
  • 12.Harvey PD, Patterson TL, Potter LS. Improvement in social competence with short-term atypical antipsychotic treatment: A randomized, double-blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning. Am J Psychiatry. 2006;163:1918–1925. doi: 10.1176/ajp.2006.163.11.1918. [DOI] [PubMed] [Google Scholar]
  • 13.Bilder RM, Goldman RS, Volavka J. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry. 2002;159:1018–1028. doi: 10.1176/appi.ajp.159.6.1018. [DOI] [PubMed] [Google Scholar]
  • 14.Saku M. The current clinical practice of herbal medicine in psychiatry in mainland China: A review of literature. Jpn J Psychiatry Neurol. 1991;45:825–832. doi: 10.1111/j.1440-1819.1991.tb00521.x. [DOI] [PubMed] [Google Scholar]
  • 15.Wang B. Traditional Chinese medical treatment to invigorate blood and relieve stasis treatment of schizophrenia: Comparison with antipsychotics treatment. Psychiatry Clin Neurosci. 1998;52(Suppl):S329–S330. doi: 10.1111/j.1440-1819.1998.tb03259.x. [DOI] [PubMed] [Google Scholar]
  • 16.Cheng HQ. Traditional Chinese Medicine. Huazhong Education University Publisher; Wuhan, China: 1988. [Google Scholar]
  • 17.Pharmacopoeia of People's Republic Nation of China. Beijing Chemistry Industry Publishing Company; Beijing, China: 2000. National pharmacopoeia commission; p. 378. [Google Scholar]
  • 18.Cai DF, Shen ZY, Chen XH. Effect of aconitine on content of corticotropin-releasing hormone in hypothalamus of rats [in Chinese] Chin J Integr Tradit West Med. 1996;16:544–546. [PubMed] [Google Scholar]
  • 19.Zhang ZQ, Huang SJ, Yuan L. Effects of Morinda officinalis oligosaccharides on performance of the swimming tests in mice and rats and the learned helplessness paradigm in rats. Chin J Pharmacol Toxicol. 2001;15:262–265. [Google Scholar]
  • 20.Cai B, Cui CB, Chen YH. Antidepressant effect of inulin-type oligosaccharides from Morinda officinalis How in mice. Chin J Pharmacol Toxicol. 1996;10:109–112. [Google Scholar]
  • 21.Meng XL, Zeng N, Zhang Y. Studies on effect of active constituents of Herba Epimedii on hypothalamic monoamines neurotransmitter and other brain functions in aging rats. China J Chin Materia Medica. 1996;21:683–687. [PubMed] [Google Scholar]
  • 22.Meng XL, Li JY, Zhang Y. Studies on neuroendocrino-immunological regulation of senile rats by using epimedium polysaccharides (EPS) Pharmacol Clin Chin Materia Medica. 1998;14:19–21. [Google Scholar]
  • 23.American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revised. American Psychiatric Association; Washington, DC: 2000. [Google Scholar]
  • 24.Habil MH, Gondoyoewono H, Chaudhry HR. Effectiveness and safety of olanzapine in the treatment of Asian outpatients with schizophrenia. Int J Clin Pharmacol Ther. 2007;45:631–642. doi: 10.5414/cpp45631. [DOI] [PubMed] [Google Scholar]
  • 25.Andreasen NC, Grove WN. Evaluation of positive and negative symptoms in schizophrenia. Psychiatry Psychobiol. 1986;1:108–121. [Google Scholar]
  • 26.Lindenmayer JP, Khan A, Iskander A. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia. J Clin Psychiatry. 2007;68:368–379. doi: 10.4088/jcp.v68n0303. [DOI] [PubMed] [Google Scholar]
  • 27.Chouinard G, Chouinard RA, Annable L, Jones BD. Extrapyramidal symptom rating scale. Can J Neurol Sci. 1980;7:3–9. [Google Scholar]
  • 28.World Medical Association Declaration of Helsinki: Recommendations Guiding Medical Doctors in Biomedical Research Involving Human Subjects [WMA Web site]. Ferney-Voltaire, France: WMA; 1989.; October 5, 2005. http://www.wma.net Accessed.
  • 29.Masiak M, Loza B. Core factors of schizophrenia structure based on PANSS and SAPS/SANS results. Discerning and head-to-head comparison of PANSS and SASPS/SANS validity. Psychiatr Pol. 2004;38:795–808. [PubMed] [Google Scholar]
  • 30.Zhang XY, Zhou DF, Cao LY. Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: A randomized double-blind study. Int Clin Psychopharmacol. 2001;16:325–330. doi: 10.1097/00004850-200111000-00002. [DOI] [PubMed] [Google Scholar]
  • 31.Hellman SG, Kern RS, Neilson LM, Green MF. Monetary reinforcement and Wisconsin Card Sorting performance in schizophrenia: Why show me the money? Schizophr Res. 1998;34:67–75. doi: 10.1016/s0920-9964(98)00088-7. [DOI] [PubMed] [Google Scholar]
  • 32.Sergi MJ, Rassovsky Y, Widmark C. Social cognition in schizophrenia: Relationships with neurocognition and negative symptoms. Schizophr Res. 2007;90:316–324. doi: 10.1016/j.schres.2006.09.028. [DOI] [PubMed] [Google Scholar]
  • 33.Heaton RK. Wisconsin Card Sorting Test Manual. Psychological Assessment Resources; Odessa, Fla: 1993. [Google Scholar]
  • 34.Xiang Y, Weng Y, Li W. Training patients with schizophrenia with the community reentry module: A controlled study. Soc Psychiatry Psychiatr Epidemiol. 2006;41:464–469. doi: 10.1007/s00127-006-0050-6. [DOI] [PubMed] [Google Scholar]
  • 35.Miller del D, Eudicone JM, Pikalov A, Kim E. Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: A post hoc analysis. J Clin Psychiatry. 2007;68:1901–1906. doi: 10.4088/jcp.v68n1210. [DOI] [PubMed] [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES